← Leaderboards
Jim Boonyaratanakornkit
Fred Hutchinson Cancer Center
$2,850,119
Attributed
$3,873,944
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2023–25$2M$1.5M$1M$500K$0
'23
'24
'25
Funding mix
By agency
NIH$3,873,944 · 2
By mechanism
R01$2,338,206 · 1
U01$1,535,738 · 1
Top collaborators
- Andrew Mcguire2 shared
- Warren Phipps2 shared
Most similar at Fred Hutchinson Cancer Center
Same institution · by research overlap
- Peter B. Gilbert$223,972,501
- Joshua Aiden Hill$6,198,358
- Denise A. Galloway$30,691,532
- Guang-Shing Cheng$3,067,611
- A. McGarry Houghton$19,684,845
Others in their field
Other Rising Stars on “Persons”
- Mari Ostendorf · University Of Washington$51,931,230
- Brian Zavertnik · Palantir Technologies, Inc.$37,240,166
- Suma Babu · Massachusetts General Hospital$36,168,406
- Sabrina Paganoni · Massachusetts General Hospital$36,168,406
- Julia Louise Moore Vogel · Scripps Research Institute, The$32,252,685
- Cyrus Wadia · Activate Global, Inc.$24,000,000
Research focus
PersonsSiteMalignant NeoplasmsNeutralizing Monoclonal AntibodiesPreventSerumEpitopesIn VivoMonoclonal AntibodiesNeutralizing AntibodyDesignAntigensBindingProphylacticAnimal ModelB-LymphocytesInfectionIn VitroAnimalsCell SeparationMortalityChildhoodAntibodiesViral
Grant awards (5)
Defining Critical Sites of Vulnerability and Correlates of Protection to Kaposi Sarcoma Associated Herpesvirus to Inform Vaccine Design$768,047
U01 · FY2025 · CA
Molecular basis and protective efficacy of cross-neutralizing antibodies against four major respiratory viruses$708,446
R01 · FY2025 · AI · contact PI
Molecular basis and protective efficacy of cross-neutralizing antibodies against four major respiratory viruses$814,880
R01 · FY2024 · AI · contact PI
Defining Critical Sites of Vulnerability and Correlates of Protection to Kaposi Sarcoma Associated Herpesvirus to Inform Vaccine Design$767,691
U01 · FY2024 · CA
Molecular basis and protective efficacy of cross-neutralizing antibodies against four major respiratory viruses$814,880
R01 · FY2023 · AI · contact PI